BSIM at the "3rd European ATTR Amyloidosis meeting for Patients and Doctors"
24 September, 2021
Earlier this month, BSIM Therapeutics attended the “3rd European ATTR Amyloidosis meeting for Patients and Doctors”, which took place virtually and was nicely organized by the “Amyloidosis Alliance” and the “UK ATTR Amyloidosis Patients’ Association” in collaboration with UCL (University College London).
The meeting was rich in informative presentations and lively discussions, virtually covering all clinical manifestations of ATTR: from cardiac to peripheral nervous system (PNS) and central nervous system (CNS) symptoms, without overlooking oculopathy, and from diagnostics and symptom management all the way to disease-modifying treatments. Sessions were neatly organized across a Doctors channel and a Patients channel. Deserving our highlight, the presentations delivered by Doctors Pablo Garcia-Pavia (Spain), Luísa Sousa (Portugal), Mathew Maurer (USA) and Yoshiki Sekijima (Japan) have drawn new attention to the increasing incidence, knowledge and impact of CNS manifestations of ATTR, especially in early diagnosed and longer surviving patients. As recalled by Doctor Maurer, the currently available therapies do not reach the CNS (or the eye) in therapeutic amounts. They are thus bound for ineffectiveness in the treatment of CNS-associated symptoms or oculopathy, which emphasizes the urgent need of more tailored and organ-targeted therapeutics.
Moreover, the increasing clinical importance of cardiac manifestations of ATTR and the efforts being made to address them through diagnostic tools and therapeutic approaches have been extensively pointed out by several speakers.
BSIM keeps on striving to develop innovative therapeutic solutions endowed with the pharmacodynamics and pharmacokinetics properties to address the unmet medical needs in ATTR.